HOME >> MEDICINE >> NEWS
Infliximab could offer long-term benefits to people with Crohns disease

Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohns disease, conclude authors of a study in this weeks issue of THE LANCET.

Crohns disease is a chronic inflammatory disorder of the intestines. Patients often have to be treated with steroids, which are associated with severe side-effects. Previous research has suggested that the drug infliximab could reduce disease symptoms in the short term; Stephen Hanauer and colleagues from the University of Chicago, USA, investigated whether treatment with infliximab every two months could be more effective in reducing the symptoms of Crohns disease in the longer term compared with a single infusion of the drug.

355 patients with severe Crohns disease from the USA, Europe, and Israel who responded within two weeks to an initial 5 mg/kg intravenous infusion of infliximab took part in the study. They were randomly assigned repeat infusions of placebo, repeat infusions of 5 mg/kg infliximab, or 10 mg/kg infliximab (after two treatments with 5mg/kg infliximab). Treatment took place at randomisation, after one month, and thereafter every two months for a year.

More than twice as many people given infliximab every two months were in remission after 30 weeks compared with patients who only received initial infliximab treatment followed by placebo. Patients given sustained infliximab responded for longer (for 38 and 54 weeks for 5mg/kg and 10mg/kg regimens, respectively) compared with patients given placebo (who only responded to treatment for an average of 19 weeks). Patients given infliximab were also more likely to discontinue use of steroids compared with those given placebo.

Stephen Hanauer comments: This study was important to demonstrate a sustained response to maintenance treatment with infliximab in Crohns disease, similar to the results with maintenance treatment for rheumatoid arthritis. After a series of inductive infusions at baseline, 2 and
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
2-May-2002


Page: 1 2

Related medicine news :

1. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
2. Novel therapy tested in mice could chase away cat allergies
3. Costs of antidepressants could have funded effective alternatives
4. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
5. Blood pressure treatment could cut risk of strokes and heart attacks
6. Proteins found in urine of pregnant women could help diagnose preeclampsia
7. Three out of the four million newborn babies who die each year could be saved
8. Increasing physician volume requirement could improve mammogram accuracy, study concludes
9. Chemicals in apples could reduce the risk of breast cancer, Cornell study in rats suggests
10. Training could remove racial bias from police reactions
11. Test could improve detection of prion disease in humans

Post Your Comments:
(Date:7/23/2014)... The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... at the UPMC/UPCI Multidisciplinary Thyroid Center and other ... getting the correct initial surgery by 30 percent, ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Men ... pay higher premiums for life insurance based on national ... cheap life insurance rates search to its comprehensive tool ... at http://quotespros.com/life-insurance.html . , Providers that are ... selected, sorted and reviewed in one or two clicks. ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... Asking patients if a suspicious skin lesion is ... spot is likely to be cancerous, according to a ... the Department of Dermatology at Temple University School of ... Dermatology on July 23, 2014, found that nearly ... by itching, while 28.2 percent involve pain. Non-melanoma skin ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
(Date:7/23/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... with respect to its naloxone-based opioid overdose reversal ... has received an additional commitment from the National ... National Institutes of Health ("NIH"), to fund a ...
(Date:7/23/2014)... CITY, Calif. , July 23, 2014  Cardica, Inc. ... release financial results for its fiscal fourth quarter and year ... the markets close. Cardica,s management will host a conference call ... and provide an update on the company,s business. ... August 7, 2014, at 4:30 p.m. Eastern Time via phone, ...
(Date:7/23/2014)... Colo. , July 23 2014 Ampio ... of its new headquarters, manufacturing and research facility: ... CO 80112 Direct: (720) 437-6500 ... labor efficient, pharmaceutical drug manufacturing facility will be fully ... produce the first batches of Ampion TM necessary ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
Cached News: